Recent Updates
Recently added Catalysts
TLRY

PRESS RELEASE

Key Takeaway: Exhibit 99.1 PRESS RELEASE July 28, 2021 Tilray, Inc. Reports 2021 Fiscal Year and Fourth Quarter Results Net Revenue Increased 27% to $513 Million Compared to Prior Year Net Income of $33.6 Million, Adjusted EBITDA of $12.3 Million, Net Cash from Operating Activities of $8.3

Full Press Release Details

Exhibit 99.1
PRESS RELEASE July 28, 2021
Tilray, Inc. Reports 2021 Fiscal Year and Fourth Quarter Results
Net Revenue Increased 27% to $513 Million Compared to Prior Year
Net Income of $33.6 Million, Adjusted EBITDA of $12.3 Million, Net Cash from Operating Activities of $8.3 Million and Positive Free Cash Flow of $3.3 Million in Q4
Completed Business Combination with Aphria Inc., Achieved $35 Million in Synergies To Date; On-track for $80 Million Target
Cannabis Revenue Grew 55% in Q4, #1 Market Share in Canada
Leading EU GMP-Certified Medical Cannabis LP in Europe with Demand Growing
Executive Leadership Executing On Plan to Drive Accelerated Growth and Sustained Profitability in Global Cannabis Market
NEW YORK and LEAMINGTON, ONTARIO - July 28, 2021 -- Tilray, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company, today reported financial results for the full fiscal year and fourth quarter ended May 31, 2021. Results for the full year and fourth quarter include legacy-Aphria's fiscal 2021 financial results and four weeks of Tilray. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated, and presented in accordance with accounting principles generally accepted in the U.S. ("GAAP").
Irwin D. Simon, Tilray's Chairman and Chief Executive Officer, stated, "Early results from the new Tilray affirm that, while the global cannabis market remains in its early stages, our vision, scale, access to resources and operational excellence position us optimally to capitalize on the opportunity. In a very short period of time since our business combination was finalized, we transformed and strengthened Tilray, delivered solid results amid continued COVID-19 lockdowns and restrictions and achieved $35 million in synergies to date - well on our way to delivering $80 million in cost savings over the next 16 months."
Mr. Simon continued, "These are early achievements but they provide the roadmap for our strategy and priorities moving forward. Tilray is now truly leading the global cannabis industry with low cost of production, leading brands, a well-developed distribution network, and unique partnerships that we believe will drive sustainable shareholder value in the quarters to come. We look forward to accelerating and refining our business-level strategies and roadmaps and to ensuring unmistakable, measurable progress as we build the leading consumer-packaged goods business in the cannabis industry."
Financial Highlights - 2021 Fiscal Fourth Quarter1
Financial Highlights- 2021 Fiscal Year
Progress on Cost-Saving Synergies and Strengthening Financial Condition
The Company expects to deliver significant cost synergies totaling approximately $80 million within eighteen months of closing the Aphria Tilray business combination and plans to achieve cost synergies in the key areas of cultivation and production, cannabis and product purchasing, sales, and marketing, and corporate expenses. To date, the Company has achieved $35 million in synergies.
Recent Business Developments Reflect Strong, Ongoing Global Growth and Opportunity
Recent Progress on Expanding International Medical Business and Canadian Adult-Use Product Line
Tilray will host a conference call to discuss these results today at 8:30 a.m. ET. Investors interested in participating in the live call can dial (877) 407-0792 from Canada and the U.S. or (201) 689-8263 from international locations.
There will also be a simultaneous, live webcast available on the Investors section of the Company's website at www.tilray.com. The webcast will also be archived after the call concludes.
Tilray, Inc. is a leading global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is changing people's lives for the better - one person at a time - by inspiring and empowering the worldwide community to live their very best life by providing them with products that meet the needs of their mind, body, and soul and invoke a sense of wellbeing. Tilray's mission is to be the trusted partner for its patients and consumers by providing them with a cultivated experience and health and wellbeing through high-quality, differentiated brands and innovative products. A pioneer in cannabis research, cultivation, and distribution, Tilray's unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and alcoholic beverages.
For more information on how we open a world of wellbeing, visit www.Tilray.com.
Cautionary Statement Concerning Forward-Looking Statements
Certain statements contained in this press release constitute "forward-looking statements" within the meaning of federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements are predictions based on expectations and projections about future events and are not statements of historical fact. You can identify forward-looking statements by the use of forward-looking terminology such as "plan," "continue," "expect," "anticipate," "intend," "predict," "project," "estimate," "likely," "believe," "might," "seek," "may," "will," "remain," "potential," "can," "should," "could," "future" and similar expressions, or the negative of those expressions, or similar words or phrases that are predictions of or indicate future events or trends and that do not relate solely to historical matters. You can also identify forward-looking statements by discussions of the Company's strategic initiatives, including productivity and synergies initiatives, our future performance and results of operations.
Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, levels of activity, performance or achievements of the Company, or industry results, to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements, and you should not rely on them as predictions of future events. Forward-looking statements depend on assumptions, data or methods that may be incorrect or imprecise and may not be able to be realized. We do not guarantee that the transactions and events described will happen as described (or that they will happen at all). Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations for our business as well as challenges and uncertainty resulting from the COVID-19 pandemic. Certain material factors, estimates, goals, projections or assumptions were used in drawing the conclusions contained in the forward- looking statements throughout this communication. Many factors could cause actual results, performance or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could
also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the Annual Report on Form 10-K of Tilray for the fiscal year ended May 31, 2021. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.
Use of Non-U.S. GAAP Financial Measures
This press release and the accompanying tables include non-GAAP financial measures, including adjusted gross margin, Adjusted EBITDA and free cash flow. Management believes that the non-GAAP financial measures presented provide useful additional information to investors about current trends in the Company's operations and are useful for period-over-period comparisons of operations. These non-GAAP financial measures should not be considered in isolation or as a substitute for the comparable GAAP measures. In addition, these non-GAAP measures may not be the same as similar measures provided by other companies due to potential differences in methods of calculation and items being excluded. They should be read only in connection with the Company's Consolidated Statements of Operations and Cash Flows presented in accordance with GAAP.
Adjusted EBITDA is calculated as net income (loss) before inventory valuation adjustments; interest expenses, net; other expenses (income), net; deferred income tax (recoveries) expenses, current income tax expenses (benefit); foreign exchange gain (loss), net; depreciation and amortization expenses; stock-based compensation expenses; loss from equity method investments; loss on disposal of property and equipment; amortization of inventory step-up; severance costs; impairment of assets; and change in fair value of warrant liability. A reconciliation of Adjusted EBITDA to net loss, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release. Gross margin, excluding inventory valuation adjustments, is calculated as revenue less cost of sales adjusted to add back inventory valuation adjustments and amortization of inventory step-up, divided by revenue. A reconciliation of Gross margin, excluding inventory valuation adjustments, to gross margin, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release. Free cash flow is comprised of two GAAP measures deducted from each other which are net cash flow provided by (used in) operating activities less investments in capital and intangible assets. A reconciliation of net cash flow provided by (used in) operating activities to free cash flow, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release.
For further information:
Media: Berrin Noorata, news@tilray.com
Investors: Raphael Gross, +1-203-682-8253, Raphael.Gross@icrinc.com
PRESENTATION OF FINANCIAL AND OTHER INFORMATION
As a result of the Arrangement on April 30, 2021, the results of operations included herein for the three months and fiscal year ended May 31, 2021 include the result of Aphria for the three and twelve months ended May 31, 2021, respectively and the results of Tilray beginning after April 30, 2021 for the one month ended May 31, 2021. The operating results for the prior periods are those of Aphria.
Consolidated Statements of Financial Position
(In thousands of United States dollars) May 31, 2021 May 31, 2020
Assets
Current assets
Cash and cash equivalents $ 488,466 $ 360,646
Accounts receivable, net 87,309 37,931
Inventory 256,429 139,781
Prepaids and other current assets 48,920 32,660
Convertible notes receivable 2,485 10,609
Total current assets 883,609 581,627
Capital assets 650,698 420,706
Right-of-use assets 18,267 5,356
Intangible assets 1,605,918 263,318
Goodwill 2,832,794 447,330
Interest in equity investees 8,106 -
Long-term investments 17,685 19,595
Other assets 8,285 -
Total assets $ 6,025,362 $ 1,737,932
Liabilities
Current liabilities
Bank indebtedness $ 8,717 $ 389
Accounts payable and accrued liabilities 212,813 112,411
Contingent consideration 60,657 -
Warrant liability 78,168 -
Current portion of lease liabilities 4,264 954
Current portion of long-term debt 36,622 6,141
Total current liabilities 401,241 119,895
Long - term liabilities
Lease liabilities 53,946 4,227
Long-term debt 167,486 94,028
Convertible debentures 667,624 196,405
Deferred tax liability 265,845 48,446
Other liabilities 3,907 -
Total liabilities 1,560,049 463,001
Commitments and contingencies - -
Shareholders' equity
Common stock 46 24
Additional paid-in capital 4,792,406 1,366,736
Accumulated other comprehensive income (loss) 152,668 (5,434 )
Deficit (486,050 ) (113,352 )
Total Tilray shareholders' equity 4,459,070 1,247,974
Non-controlling interests 6,243 26,957
Total shareholders' equity 4,465,313 1,274,931
Total liabilities and shareholders' equity $ 6,025,362 $ 1,737,932
Condensed Consolidated Statements of Net Income (Loss) and Comprehensive Income (Loss)
Three months ended May 31, Years ended May 31,
(In thousands of United States dollars, excpet for per share data) 2021 2020 2021 2020
Net revenue $ 142,236 $ 113,542 $ 513,085 $ 405,326
Cost of goods sold 119,738 85,735 389,903 309,273
Gross profit 22,498 27,807 123,182 96,053
Operating expenses:
General and administrative 32,847 24,913 111,575 93,789
Selling 8,525 7,320 26,576 18,975
Amortization 16,100 3,645 35,221 15,138
Marketing and promotion 5,103 2,874 17,539 15,266
Research and development 358 430 830 1,916
Impairment - 50,679 - 50,679
Transaction costs 33,260 1,387 63,612 4,299
Total operating expenses 96,193 91,248 255,353 200,062
Operating loss (73,695 ) (63,441 ) (132,171 ) (104,009 )
Finance income (expense), net (9,466 ) (6,411 ) (27,977 ) (19,371 )
Non-operating income (expense), net 121,510 (17,351 ) (184,838 ) 14,195
Income (loss) before income taxes 38,349 (87,203 ) (344,986 ) (109,185 )
Income taxes (recovery) 4,744 (2,897 ) (8,972 ) (8,352 )
Net income (loss) $ 33,605 $ (84,306 ) $ (336,014 ) $ (100,833 )
Earnings (Loss) per share - basic and diluted $ 0.18 $ (0.39 ) $ (1.25 ) $ (0.47 )
Net Revenue by Operating Segment
(In thousands of United States dollars) Three Months Ended May 31, 2021 % of Total revenue Three Months Ended May 31, 2020 % of Total revenue
Cannabis revenue $ 53,703 38% $ 39,587 35%
Distribution revenue 66,792 47% 73,955 65%
Beverage alcohol revenue 15,947 11% - 0%
Wellness revenue 5,794 4% - 0%
Net revenue $ 142,236 100% $ 113,542 100%
(In thousands of United States dollars) Year Ended May 31, 2021 % of Total revenue Year Ended May 31, 2020 % of Total revenue
Cannabis revenue $ 201,392 39% $ 129,896 32%
Distribution revenue 277,300 54% 275,430 68%
Beverage alcohol revenue 28,599 6% - 0%
Wellness revenue 5,794 1% - 0%
Net revenue $ 513,085 100% $ 405,326 100%
(In thousands of United States dollars, except for percent data)
Three months ended May 31, Years ended May 31,
Adjusted EBITDA Reconciliation 2021 2020 2021 2020
Net income (loss) $ 33,605 $ (84,306 ) $ (336,014 ) $ (100,833 )
Income taxes 4,744 (2,897 ) (8,972 ) (8,352 )
Finance expense, net 9,466 6,411 27,977 19,371
Non-operating expense (income), net (121,510 ) 17,351 184,838 (14,195 )
Amortization 24,539 10,320 67,832 35,669
Share-based compensation 5,937 3,799 17,351 18,079
Impairment - 50,679 - 50,679
Inventory valuation adjustments 19,919 - 19,919 -
Purchase price accounting step up - - 835 -
Facility start-up costs 2,056 467 2,056 -
Lease expense 303 - 1,337 1,128
Transaction costs 33,260 1,387 63,612 4,299
Adjusted EBITDA $ 12,319 $ 3,211 $ 40,771 $ 5,845
Three months ended May 31, Years ended May 31,
Key Operating Metrics 2021 2020 2021 2020
Net cannabis revenue $ 53,703 $ 39,587 $ 201,392 $ 129,896
Net beverage alcohol revenue 15,947 - 28,599 -
Distribution revenue 66,792 73,955 277,300 275,430
Wellness revenue 5,794 - 5,794 -
Cannabis cost of sales 49,731 20,692 130,511 68,551
Beverage alcohol cost of sales 5,349 - 12,687 -
Distribution cost of sales 60,425 65,043 242,472 240,722
Wellness cost of sales 4,233 - 4,233 -
Gross profit (excluding adjustments) 42,417 27,808 143,936 96,053
Cannabis gross margin (excluding adjustments) 44.5 % 47.7 % 45.1 % 47.2 %
Beverage gross margin (excluding adjustments) 66.5 % - 58.6 % -
Distribution gross margin (excluding adjustments) 9.5 % 12.1 % 12.6 % 12.6 %
Wellness gross margin (excluding adjustments) 26.9 % - 26.9 % -
Adjusted EBITDA 12,319 3,211 40,771 5,845
Cash and cash equivalents 488,466 360,646 488,466 360,646
Working capital 482,368 349,320 482,368 349,320
Three months ended May 31, Years ended May 31,
Free Cash Flow 2021 2020 2021 2020
Net cash provided by (used in) operating activities $ 8,281 $ (7,367 ) $ (44,715 ) $ (100,627 )
Less: investments in capital and intangible assets 4,943 20,908 38,874 98,786
Free cash flow 3,338 (28,275 ) (83,589 ) (199,413 )
Three months ended May 31, 2021
Gross profit (excluding adjustments) Cannabis Beverage Distribution Wellness Total
Gross revenue $ 71,358 $ 16,549 $ 66,792 $ 5,794 $ 160,493
Excise taxes (17,655 ) (602 ) - - (18,257 )
Net revenue 53,703 15,947 66,792 5,794 142,236
Cost of goods sold 49,731 5,349 60,425 4,233 119,738
Gross profit 3,972 10,598 6,367 1,561 22,498
Gross margin 7 % 66 % 10 % 27 % 16 %
Adjustments:
Inventory valuation adjustment 19,919 - - - 19,919
Purchase price accounting step up - - - - -
Adjusted gross profit 23,891 10,598 6,367 1,561 42,417
Adjusted gross margin 44 % 66 % 10 % 27 % 30 %
Three months ended May 31, 2020
Gross profit (excluding adjustments) Cannabis Beverage Distribution Wellness Total
Gross revenue $ 48,833 $ - $ 73,955 $ - $ -
Excise taxes (9,246 ) - - - -
Net revenue 39,587 - 73,955 - 113,542
Cost of goods sold 20,692 65,043 - 85,735
Gross profit 18,895 - 8,912 - 27,807
Gross margin 48 % - % 12 % - % 24 %
Adjustments:
Inventory valuation adjustment - - - - -
Purchase price accounting step up - - - - -
Adjusted gross profit 18,895 - 8,912 - 27,807
Adjusted gross margin 48 % - % 12 % - % 24 %
Gross profit Year ended May 31, 2021
Gross profit (excluding adjustments) Cannabis Beverage Distribution Wellness Total
Gross revenue $ 264,334 $ 29,661 $ 277,300 $ 5,794 $ 577,089
Excise taxes (62,942 ) (1,062 ) - - (64,004 )
Net revenue 201,392 28,599 277,300 5,794 513,085
Cost of goods sold 130,511 12,687 242,472 4,233 389,903
Gross profit 70,881 15,912 34,828 1,561 123,182
Gross margin 35 % 56 % 13 % 27 % 24 %
Adjustments:
Inventory valuation adjustment 19,919 - - - 19,919
Purchase price accounting step up - 835 - - 835
Adjusted gross profit 90,800 16,747 34,828 1,561 143,936
Adjusted gross margin 45 % 59 % 13 % 27 % 28 %
Year ended May 31, 2020
Gross profit (excluding adjustments) Cannabis Beverage Distribution Wellness Total
Gross revenue $ 153,477 $ - $ 275,430 $ - $ 428,907
Excise taxes (23,581 ) - - - (23,581 )
Net revenue 129,896 - 275,430 - 405,326
Cost of goods sold 68,551 - 240,722 - 309,273
Gross profit 61,345 - 34,708 - 96,053
Gross margin 47 % - % 13 % - % 24 %
Adjustments:
Inventory valuation adjustment - - - - -
Purchase price accounting step up - - - - -
Adjusted gross profit 61,345 - 34,708 - 96,053
Adjusted gross margin 47 % - % 13 % - % 24 %
Last updated: Jul 28, 2021